The Future of Retinal Imaging Has Arrived!

Joseph J. Pizzimenti, OD, FAAO

Carlo Pelino, OD, FAAO




Financial Disclosure

- Pizzimenti:
- Honoraria
 - Kemin
 - Nicox
 - Review of Optometry
 - Optometric Management
 - VSP
- Scientific Advisory Boards
 - Zeavision
 - Zoice
 - Thrombogenics
- Pelino: nothing to disclose



Goals of this Course

- To provide a broad overview of Post Seg Imaging
- Past, Present, and ...
- Clinical Applications and Interpretation



Imaging Technologies

- Fundus photography
- Wide-field/panoramic
- Angiography
 - Fluorescein (FA)
- Indocyanine Green (ICGA)
- Scanning lasers
 - OCT
 - En faceEnhanced depth
 - Enhanced depOCTAng



Imaging Technologies

- Fundus
 - Autofluorescence (FAF)
- A/B Scan Ultrasound (Echography)
- Multi-spectral imaging
- Adaptive optics




Questions and Comments?




"Most major advances in the understanding of retinal diseases have been preceded by advances in imaging."

> Richard Spaide, MD NY Retina Consultants



Optos Wide-Field Angiography





Digital retinal imaging does not replace a dilated retinal examination.


Fundus Biomicroscopy and BIO


Milestones in Retinal Imaging

■ Fundus Photography	1920s
■ Fluorescein Angiography	1950s
■ B-Scan Ultrasound	1970s
■ ICG Angiography (Digital)	1980s
■ CSLO (HRT), SLP (GDX)	1990s
 OCT first demonstrated 	1991
■ High-res OCT	2001
■ Fourier (Spectral) Domain OCT	2007









The Critical Question

Will this technology improve patient care?

How can imaging technologies help me grow my practice?

Benefits of Post Seg Imaging

- Provide a higher level of care for our patients
 - Less referrals to sub-specialists (Dry AMD, CSC, Nevus)
 - Keep care in-house, keep revenues in house
- Use our new technology as a marketing tool to attract new patients: A/B-scan, OCT, FAF, wide retinal field imaging
 - These important tests also generate revenue
- I get referrals from many local ODs. You can too.
 - Become a recognized expert by reading and using the

There are many treatments, but....



Macular Pigment Optical Density (MPOD)

Heterochromatic Flicker Photometry

The Importance of Macular Pigment

- · Filters blue light
- Acts as an antioxidant by quenching free radicals
- Provides support to sensory retina MPOD is a biomarker of retina and systemic health (DM, cog

Macular Pigment




MPOD



Measurement of Macular Pig Optical Density (MPOD)


HFP works on the principle that:


- Macular pigment absorbs blue light (not green light)
- · Dense or thicker macular pigment = longer time to see the target begin to flicker
- · Results are quantified in density units (du)





What is Multicolor Imaging (MCI)?

- Simultaneous imaging with multiple laser colors.
- MCI selectively captures diagnostic information originating from different posterior segment structures and layers within a single scan.
- Delivers high contrast, detailed images and en face slices.
- A simultaneous SD-OCT image can be obtained for <u>multi-modal</u> analysis.











What is Multispectral Imaging (MSI)?

- The use of several non-overlapping discrete spectral bands, or slices, to highlight certain features within the field of view.
- Produces discrete en face slices of posterior segment tissue.
- FAF possible.





How does MSI work?


- MSI uses discrete light emitting diodes (LEDs) across a wavelength range from 520 nm (green) to 940 nm (infrared).
- Progressively images the layers of the sensory retina, RPE, and choroid.
- Longer wavelengths penetrate deeper into the tissues.




Confocal Scanning In TrueColor confocal fundus photography white light is flashed onto the retina and gets reflected back to the sensor Image quality is NOT affected by cataract and other media opacities because light reflected by other layers crossed (cornea, aqueous, lens, vitreous) is filtered and does NOT contributes to image formation Image quality is less affected by pupil size (min 2.5 mm)









Scanning Laser Match Game Instruments Technologies OCT Confocal scanning le


- HDT 3
- HRT 3
- GDX
- Confocal scanning laser ophthalmoscopy (CLSO)Scanning laser
- Scanning laser polarimetry (SLP)
- Low Coherence Interferometry

Scanning Laser Match Game Instruments Technologies

- OCT H
- HRT 3
- GDX
- Confocal scanning laser ophthalmoscopy (CLSO)
- Scanning laser polarimetry (SLP)
- Low Coherence Interferometry

Scanning Laser Match Game

- OCT
- Low Coherence Interferometry
- HRT 3
- Confocal scanning laser ophthalmoscopy (CLSO)
- GDX
- Scanning laser polarimetry (SLP)






Optical Coherence Tomography

Unlike FA, OCT is non-invasive.

Posterior Segment Applications

- Vitreous/Vitreoretinal Interface
- Neurosensory retina, RPE/Bruch's
- Choriocapillaris/Deeper Choroid (EDI)
- Optic Nerve/NFLA



Coverage for OCT

■ Anterior Seg 92132

■ Glaucoma/ON 92133


■ Retina 92134


Coding Caveats

- These codes are only billed once, whether you scan both eyes or just one.
- 92133 and 92134 are mutually exclusive, so they cannot be billed on same day, regardless of diagnosis.
- In many areas, 92132 is also considered to be inappropriate to bill on the same day with either of the posterior segment procedures.
- Check your local LCD.

Questions and Comments?









TOMography: cut/cross-section CAT, MRI, OCT, B-Scan

TOPography: relief/mapping Corneal Top



- A cross-sectional tomograph is achieved by laterally combining a series of A-scans.
- Two-dimensional data sets are digitized by a computer and presented as a gray-scale or false-color image.

Identification of Retinal Layers-TD





Cross-sectional image of live tissue; a "virtual biopsy"


SD-OCT Healthy Macula





SD-OCT Healthy Macula w/Layers













- Vitreous/Vitreoretinal Interface
- Neurosensory retina, RPE
- Choriocapillaris


■ Optic Nerve/NFLA





The Vitreoretinal Interface





retinalphysician.com
















The Vitreous





MIVI-TRUST Program

- Microplasmin for IntraVitreous Injection-Traction Release withoUt Surgical Treatment
- Two randomized, placebo controlled, doublemasked, multi-center trials (Phase III)
 - single-dose 125-µg intravitreal Ocriplasmin (ThromboGenics) v. placebo for symptomatic VMA.
- Primary endpoint of both trials was resolution of VMA one month after injection.
- Over 650 patients were enrolled
- 90 centers in 7 countries.

Goal: Complete PVD




Results

- At 28 days, VMA resolved in 29.8% of 464 eyes treated with Ocriplasmin and 7.7% of 188 eyes given placebo.
- Total posterior detachment occurred in 17% of treated eyes.
- Moreover, 25.5% of treated eyes gained two or more lines of acuity at 6 months.
- At 6 months, 40.6% of treated eyes achieved fullthickness macular hole closure, compared with only 17% of placebo eyes.


Questions and Comments?







The Posterior Hyaloid in AMD

- If microplasmin can successfully produce a PVD, there may be some future therapeutic benefit in the prevention of progression to wet AMD.
 - Sebag J, Binder S. Posterior hyaloid adhesion is significantly increased in NV AMD. Program and abstracts of the 40th Annual Scientific Meeting of the Retina Society; September 27-30, 2007; Boston, Massachusetts.



VMA may precipitate Macular Edema in DR, RVO





Status of Ocriplasmin Pharmacologic Vitreolysis

- ThromboGenics gained FDA approval and brought Ocriplasmin to market in the U.S. in January 2013.
- New unique ICD-9-CM disease code approved specifically for vitreomacular adhesion (VMA).
- ICD-9 = 379.27



Indication

JETREA® (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Good Candidates for Jetrea

- Small VMA area
 - <1,500 microns
- No ERM
- Stage 2 MH
- Younger
 - < 65 y/o
- Phakic



Poor Candidates for Jetrea


- Eyes w/multiple VMAs
- High myopia (greater than 8.00D)
- Hx of prior RD
- Macular hole greater than 400µm
- ERM
- Ischemic retinal disease




S/P Jetrea


Most patients experience worsening of symptoms, i.e., flashes, floaters and/or reduced vision, before they improve.


Anti-Integrin Peptide for VMA






- Phase II study of anti-integrin oligopeptide (ALG-1001) in patients with vitreomacular traction (VMT).
- Also treats CNV.
- David Boyer, MD







Watzke-Allen Test

- Subjective
- Purpose: identify fullthickness v. lamellar
- Fundus lens at SL
- Vertical beam
- Central break indicates full-thickness
- Maddox rod, direct scope







ERM With Mac Pucker, Pseudohole




ERM en Face (Slab Analysis)








- Vitreous/Vitreoretinal Interface
- Neurosensory retina, RPE/Bruch's
- Choriocapillaris
- Optic Nerve/NFLA










































- Vitreous/Vitreoretinal Interface
- Neurosensory retina, RPE/Bruch's
- Choroid
- Optic Nerve/NFLA




















- Vitreous/Vitreoretinal Interface
- Neurosensory retina, RPE
- Choriocapillaris
- Optic Nerve/NFLA







































































$\frac{Advanced\ Visualization\ Analysis}{\text{Manipulation\ of\ Images\ on\ OCT}}$















Case

- 65 Year old Female
- Comes in with complaints of blurred and dimmed vision
- PMH: Rheumatoid Arthritis x 15 years
- OcHx: S/P CE and IOL OU


Ophthalmic Exam


- VA:
 - OD: 20/40 OS: 20/40
- IOP
 - OD: 14 OS: 13
- SLE:
 - -OD: PCIOL OS: PCIOL
- DFE:


DFE/OCT












Fundus Autofluorescence

While Angiography images BRB integrity, FAF captures metabolic activity.



Likely Diagnosis?

Plaquenil Maculopathy

- Co-management team includes eye care provider, rheumatology
- Testing guidelines for patients on Plaquenil
- Repeat testing

Fundus Autofluorescence

While Angiography images BRB integrity, FAF captures metabolic activity.

Imaging Technologies: FAF

Hyper-AF



Hypo-AF

Imaging Technologies: FAF

What is autofluorescence in the retina?

■ It is the fluorescence of the lipofuscin molecule within the RPE cell layer that fluoresces with a certain wavelength.






rs

Autofluorescence (FAF)


- Principle
 - When stimulated with light in the blue range, lipofuscin granules emit yellow fluorescence.
 - Patterns of fundus autofluorescence may predict which eyes will progress more quickly.





Autofluorescence


Autofluorescence (FAF)


- Early ID of disease.
 - ON drusen
 - CSC
- Predictive marker
 - increased FAF signal precedes dry AMD progression.
- Monitor Dx.
- Functional correlation.




























Digital Video Imaging





Macular Hole Sx. ILM Peel



Summary and Conclusions

- No imaging technology replaces the skills of a good historian, diagnostician, clinician.
- Clinicians are better equipped than ever to detect and characterize sight-threatening posterior segment disease early.
- Timely treatment with more effective therapies enhance the potential for <u>improved visual</u> <u>outcomes</u>.

Thank you!

